MA53050A1 - Solutions oromuqueuses de zolpidem ou sels pharmaceutiquement acceptables de celles-ci - Google Patents

Solutions oromuqueuses de zolpidem ou sels pharmaceutiquement acceptables de celles-ci

Info

Publication number
MA53050A1
MA53050A1 MA53050A MA53050A MA53050A1 MA 53050 A1 MA53050 A1 MA 53050A1 MA 53050 A MA53050 A MA 53050A MA 53050 A MA53050 A MA 53050A MA 53050 A1 MA53050 A1 MA 53050A1
Authority
MA
Morocco
Prior art keywords
zolpidem
pharmaceutically acceptable
formulations
acceptable salts
allow
Prior art date
Application number
MA53050A
Other languages
English (en)
Other versions
MA53050B1 (fr
Inventor
Ketan R Patel
Milan R Patel
Asheel K Patel
Nisheel K Patel
Kush M Patel
Original Assignee
Troikaa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Troikaa Pharmaceuticals Ltd filed Critical Troikaa Pharmaceuticals Ltd
Publication of MA53050A1 publication Critical patent/MA53050A1/fr
Publication of MA53050B1 publication Critical patent/MA53050B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne des formulations buccales ou sublinguales de zolpidem ou un sel pharmaceutiquement acceptable de celles-ci. Les formulations réduisent au minimum la quantité d'amplificateurs de pénétration tout en assurant une pénétration transmucosale rapide du médicament. Ces formulations permettent non seulement une concentration souhaitée (0,5 % à 10 % p/v) du médicament sous la forme d'une solution claire, mais permettent également d'obtenir des formulations stables pendant toute la durée de conservation qui est d'au moins environ 2 ans. Le ph des solutions non aqueuses stables de la présente invention est compris entre 5 et 9, de préférence entre 6 et 9, et de préférence encore entre 7 et 9.
MA53050A 2018-10-08 2019-10-04 Solutions oromuqueuses de zolpidem ou sels pharmaceutiquement acceptables de celles-ci MA53050B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821038060 2018-10-08
PCT/IN2019/050734 WO2020075183A1 (fr) 2018-10-08 2019-10-04 Solutions oromuqueuses de zolpidem ou sels pharmaceutiquement acceptables de celles-ci

Publications (2)

Publication Number Publication Date
MA53050A1 true MA53050A1 (fr) 2022-06-30
MA53050B1 MA53050B1 (fr) 2023-03-31

Family

ID=68296607

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53050A MA53050B1 (fr) 2018-10-08 2019-10-04 Solutions oromuqueuses de zolpidem ou sels pharmaceutiquement acceptables de celles-ci

Country Status (26)

Country Link
US (1) US20220000845A1 (fr)
EP (1) EP3863604A1 (fr)
JP (1) JP2022501407A (fr)
KR (1) KR20210074311A (fr)
CN (1) CN112996488A (fr)
AR (1) AR116721A1 (fr)
AU (1) AU2019358394A1 (fr)
BR (1) BR112021006551A2 (fr)
CA (1) CA3115195A1 (fr)
CL (1) CL2021000856A1 (fr)
CO (1) CO2021005969A2 (fr)
DO (1) DOP2021000060A (fr)
EA (1) EA202190765A1 (fr)
EC (1) ECSP21024213A (fr)
GE (1) GEP20237492B (fr)
IL (1) IL282020A (fr)
JO (1) JOP20210068A1 (fr)
MA (1) MA53050B1 (fr)
MX (1) MX2021003975A (fr)
PE (1) PE20211007A1 (fr)
PH (1) PH12021550748A1 (fr)
SG (1) SG11202103255RA (fr)
TN (1) TN2021000051A1 (fr)
UY (1) UY38405A (fr)
WO (1) WO2020075183A1 (fr)
ZA (1) ZA202102322B (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
EP2042161A1 (fr) 1997-10-01 2009-04-01 Novadel Pharma Inc. Composition sans propulseurs appliquée par pulvérisation contenant un agent antiémétique
JP2006516963A (ja) * 2003-02-04 2006-07-13 クリサリス テクノロジーズ インコーポレイテッド エアロゾル製剤及びブスピロン、ブプレノルフィン、トリアゾラム、シクロベンザプリン及びゾルピデムのエアロゾル送出
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CA2556450C (fr) * 2004-02-17 2013-08-06 Transoral Pharmaceuticals, Inc. Compositions permettant d'administrer des agents hypnotiques dans la muqueuse orale et methodes d'utilisation
US7658945B2 (en) * 2004-02-17 2010-02-09 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
GB0423800D0 (en) 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
JP5577021B2 (ja) * 2005-02-17 2014-08-20 アボット・ラボラトリーズ 動物における障害を治療および予防するための薬剤組成物の経粘膜投与
BRPI0609984A2 (pt) * 2005-05-25 2010-05-18 Transcept Pharmaceuticals Inc uso de zolpidem ou um sal do mesmo
CA2649895C (fr) * 2006-04-19 2013-03-26 Novadel Pharma Inc. Formulations hydroalcooliques stables a pulveriser dans la cavite buccale et procedes associes
WO2008141264A1 (fr) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Compositions et procédés anti-insomnie
CN101842079B (zh) * 2007-08-31 2012-09-05 阿基米德开发有限公司 非水性药物组合物
US20090246256A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
CN101780038A (zh) * 2010-03-30 2010-07-21 上海现代药物制剂工程研究中心有限公司 酒石酸唑吡坦口腔喷雾剂及其制备方法
PE20131492A1 (es) * 2010-10-12 2014-01-17 Ivax Pharmaceuticals Ireland Dispositivo pulverizador nasal

Also Published As

Publication number Publication date
MA53050B1 (fr) 2023-03-31
ZA202102322B (en) 2023-01-25
CN112996488A (zh) 2021-06-18
BR112021006551A2 (pt) 2021-07-06
ECSP21024213A (es) 2021-06-30
PE20211007A1 (es) 2021-06-01
MX2021003975A (es) 2021-05-27
AU2019358394A1 (en) 2021-05-06
DOP2021000060A (es) 2021-08-31
EP3863604A1 (fr) 2021-08-18
JP2022501407A (ja) 2022-01-06
US20220000845A1 (en) 2022-01-06
EA202190765A1 (ru) 2021-07-01
WO2020075183A1 (fr) 2020-04-16
UY38405A (es) 2020-03-31
JOP20210068A1 (ar) 2023-01-30
TN2021000051A1 (en) 2022-10-03
CO2021005969A2 (es) 2021-05-20
PH12021550748A1 (en) 2022-02-14
KR20210074311A (ko) 2021-06-21
IL282020A (en) 2021-05-31
CL2021000856A1 (es) 2021-09-24
GEP20237492B (en) 2023-04-10
SG11202103255RA (en) 2021-04-29
CA3115195A1 (fr) 2020-04-16
AR116721A1 (es) 2021-06-09

Similar Documents

Publication Publication Date Title
ATE520317T1 (de) Getränkzusammensetzung
LU93066I2 (fr) Combinaison de a) olodatérol, isomèrers optiques individuels de celui-ci, melanges d'énantionmères indiviou de recémates, leurs sels d'addition d'acide avec des acides pharmaceutiquement acceptables, éventuellement sous forme de solvates et/ou hycrates, et b.) un sel de tiotropium ; en particulier une combinaison de a) olodatérol et sis sels d'addition d'acide avec des acides pharmaceutiquement acceptables et b.) du bromure de tiotropium, éventuellement sous forme de solvate et/ou hydrate , plus particulièrement une combinaison de a) hadrochlorure d'olodatérol et b.) de bromure de tiotropium, éventuellement sous forme de monohydrate
MA33374B1 (fr) Composition de surfactant reconstitué améliorée contenant des analogues de la protéine b du surfactant (sp-b) et de la protéine c du surfactant (sp-c)
WO2007125545A3 (fr) Composition transmucosale
PE20060210A1 (es) 8-[3-amino-piperidin-1-il]-xantinas como inhibidores de dpp-iv
DK1408911T3 (da) Terapeutiske bioadhæsive systemer med forhalet frigivelse
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
NO20053277D0 (no) Hurtigvirkende farmasoytisk sammensetning.
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
PE20130615A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
GT200600431A (es) Formulacion acuosa hfsh
EA200100749A1 (ru) Синтетические пептиды, обладающие поверхностной активностью, и их применение для приготовления синтетического сурфактанта
RU2020123357A (ru) Пептиды, имеющие протеазную активность, для применения при лечении или профилактике коронавирусной инфекции
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
MA53050A1 (fr) Solutions oromuqueuses de zolpidem ou sels pharmaceutiquement acceptables de celles-ci
EA200900095A1 (ru) Лекарственные формы бифосфонатов для ингаляции и способы их применения
AR036265A1 (es) Uso de bibn4096 en combinacion con otros farmacos antimigranosos para el tratamiento de migrana
Reichart et al. Candida‐associated palatal papillary hyperplasia in HIV infection
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
PE20060296A1 (es) Composicion farmaceutica que contiene interferon muteina
ES2131482B1 (es) Formulacion acuosa de bambuterol.
MA58173B1 (fr) Composition liquide comprenant de l'ibuprofène et de la phényléphrine
CO4820436A1 (es) Mezclas solidas utiles para combatir el crecimiento de las plantas indeseadas, procedimiento de preparacion y aplica- cion
WO2003103610A3 (fr) Analogues de mappicines, procedes d'inhibition de transcriptase inverse retrovirale et methodes de traitement de retrovirus
FR3120793B1 (fr) Agents solubilisants et compositions les comprenant